Your prediction
Sonnet Biotherapeutics Holdings Inc. Stock
Our community identified positive and negative aspects for Sonnet Biotherapeutics Holdings Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Sonnet Biotherapeutics Holdings Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Sonnet Biotherapeutics Holdings Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
M***** P*******
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Sonnet Biotherapeutics Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sonnet Biotherapeutics Holdings Inc. | - | - | - | - | - | - | - |
| Skylark Co Ltd | 0.590% | -5.056% | -4.520% | -5.056% | -5.056% | 43.220% | 33.071% |
| J D Wetherspoon plc | 0.690% | 4.478% | -5.405% | 1.449% | -15.152% | -17.501% | -55.128% |
| SSP Group plc | 3.520% | 2.577% | 1.015% | 37.241% | -8.716% | -27.372% | -43.594% |
Comments
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $20.00 price target on the stock.
Show more
Ratings data for SONN provided by MarketBeat
Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) had its price target lowered by analysts at Chardan Capital from $30.00 to $20.00. They now have a "buy" rating on the stock.
Show more
Ratings data for SONN provided by MarketBeat